A.Giaccari1 · G. Gliozzo1 · G. Ciccarelli1 · G. Di Giuseppe1 · C. Castellano2 · S. Cum3 · L. Delle Monache4,13 · M. Gallo5 ·M.Lastretti6 · G. Medea7 · M. Monesi8 · R. Napoli9 · B. Pintaudi10 · E. Succurro11 · G. Turchetti
Received: 9 January 2026 / Accepted: 17 March 2026 © The Author(s) 2026
Abstract
Background and aims Although continuous glucose monitoring (CGM) devices are now standard of care among Type 1 diabetes patients, they are still relatively underutilized in Type 2 diabetes (T2D), particularly in those patients not treated with insulin. Widespread adoption continues to be hindered by a combination of factors. Chief among these is the scarcity of long-term, large-scale clinical trials demonstrating the benefits of the use of CGM in T2D. This meta-analysis aimed to address this gap by comparing CGM with self-blood glucose monitoring (SBMG), with primary outcomes of HbA1c and time in range (TIR) in insulin-treated and non-insulin-treated TD2 patients.
Methods and results Following the stringent rules mandated by our National Health Service (which requires a panel com-posed of all stakeholders involved in diabetes treatment, and includes PICO, GRADE, AGREE, and meta-analyses), we performed a systematic review of RCTs that enrolled two groups of individuals with T2D, those treated with insulin (includ-ing basal and basal-bolus regimens), and those receiving treatments other than insulin. All included trials compared CGM with structured blood glucose monitoring (SBGM) with glycated hemoglobin (HbA1c) as the main endpoint. Based on the strength and consistency of the evidence, the panel issued a strong recommendation in favor of CGM for individuals with T2D treated with insulin (including those on basal insulin alone) and for individuals with T2D not treated with insulin, par-ticularly for those with glycated hemoglobin levels≥7%. From a pharmacoeconomic perspective, outcomes were positive in both patient groups.
Conclusion CGM represents a clinically effective and cost-efficient approach to optimizing glycemic control in T2D, becom-ing mandatory among individuals on insulin therapy. Our findings support a shift in clinical practice toward the more widespread use of CGM in T2D, with regulatory frameworks and reimbursement policies needing to adapt accordingly.
Keywords CGM · Type 2 Diabetes · Metanalysis · PICO · GRADE · Guidelines
Communicated by Massimo Federici, M.D.
A. Giaccari 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
1 Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy
2 Azienda USL of Modena, Sassuolo Hospital, Sassuolo, Italy
3 Diabetes and Diabetic Foot Care Unit, ASUGI, Monfalcone, Italy
4 National Board Member of FAND (Italian Association for the Rights of Diabetic People), Roma, Italy
5 Department of Endocrinology and Metabolic Diseases, AO SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6 Order of Psychologists of Lazio, Rome, Italy
7 Italian Society of General Medicine (SIMG), Florence, Italy
8 Territorial Diabetology Unit, AUSL Ferrara, Ferrara, Italy
9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
10 Diabetes Unit, Niguarda Cà Granda Hospital, Milan, Italy
11 Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
12 Institute of Management, Scuola Superiore Sant’Anna, Pisa, Italy
13 Patient Advocacy Lab, ALTEMS – Università Cattolica del Sacro Cuore, Rome, Italy
版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章。
引用本文:简喜超, 简扬, 邓呈亮. 2025版《中国糖尿病足防治实践指南》解读[J]. 中华医学美学美容杂志, 2026, 32(2): 99-103. DOI: 10.3760/cma.j.cn114657-20251215-00266.
通信作者:邓呈亮,Email:该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
Clarisse Ganiera,1 , Pavel Mazinb , Gabriel Herrera-Oropezac , Xinyi Du-Harpura,d, Matthew Blakeleya , Jeyrroy Gabriela , Alexander V. Predeusb ,
Batuhan Cakirb , Martin Preteb , Nasrat Haruna , Jean-Francois Darrigranda , Alexander Haisera , Saranya Wylese , Tanya Shawf , Sarah A. Teichmannb,g,
Muzlifah Haniffab,h,i, Fiona M. Watta,j,1,2 , and Magnus D. Lyncha,k,1,2
Contributed by Fiona M. Watt; received August 6, 2023; accepted November 13, 2023; reviewed by Vladimir Botchkarev and Valerie Horsley
Our understanding of how human skin cells differ according to anatomical site and tumour formation is limited. To address this, we have created a multiscale spatial atlas of healthy skin and basal cell carcinoma (BCC), incorporating in vivo optical coherence tomography, single-cell RNA sequencing, spatial global transcriptional profiling, and in situ sequencing. Computational spatial deconvolution and projection revealed the localisation of distinct cell populations to specific tissue contexts. Although cell populations were conserved between healthy anatomical sites and in BCC, mesenchymal cell populations including fibroblasts and pericytes retained signatures of developmental origin. Spatial profiling and in silico lineage tracing support a hair follicle origin for BCC and demonstrate that cancer-associated fibroblasts are an expansion of a POSTN+ subpopulation associated with hair follicles in healthy skin. RGS5+ pericytes are also expanded in BCC suggesting a role in vascular remodelling. We propose that the identity of mesenchymal cell populations is regulated by signals emanating from adjacent structures and that these signals are repurposed to promote the expansion of skin cancer stroma. The resource we have created is publicly available in an interactive format for the research community.
human cell atlas | skin | basal cell carcinoma | single cell RNA sequencing | fibroblasts
Significance
Single-cell RNA sequencing (scRNAseq) has revolutionised cell biology, enabling highresolution analysis of cell types and states within human tissues. Here, we report a comprehensive spatial atlas of adult human skin across different anatomical sites and basal cell carcinoma (BCC)— the most common form of skin cancer—encompassing in vivo optical coherence tomography, scRNAseq, global spatial transcriptomic profiling, and in situ sequencing. In combination, these modalities have allowed us to assemble a comprehensive nuclearresolution atlas of cellular identity in health and disease.
Author contributions: C.G., F.M.W., and M.D.L. designed research; C.G., X.D.-H., M.B., J.G., and N.H. performed research; C.G., G.H.-O., X.D.-H., A.V.P., B.C., M.P., J.-F.D., A.H., T.S., S.A.T., and M.H. contributed new reagents/ analytic tools; C.G., P.M., G.H.-O., A.V.P., B.C., M.P., A.H., S.W., and M.D.L. analyzed data; and C.G., F.M.W., and M.D.L. wrote the paper.
Reviewers: V.B., Boston University School of Medicine; and V.H., Yale University.
Competing interest statement: In the last 3 y, S.A.T. has been a remunerated Scientific Advisory Board member for GlaxoSmithKline, Qiagen, Foresite Labs, and is a cofounder and equity holder of TransitionBio. F.M.W. and M.D.L. are co-founders of Fibrodyne. F.M.W. and M.D.L. have filed two patents related to skin fibroblasts. Copyright © 2024 the Author(s). Published by PNAS.
This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).
1 To whom correspondence may be addressed. Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。, or magnus. 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.
2 F.M.W. and M.D.L. contributed equally to this work. This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas. 2313326120/-/DCSupplemental.
Published January 2, 2024.
Qiong Chen1 | Lin Liu2 | Yi Zhang1
1 The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shanghai, China
2 Dermatology Department, Jingfu Medical Beauty Hospital of Chunxi Road Ward, Chengdu, China
Correspondence
Yi Zhang, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shanghai, China.
Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2024 The Authors. International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Chloasma, which is distinguished by irregularities in the pigmentation of skin, poses substantial challenge in the field of dermatology. The regulatory influence of vitamin D on the functions of skin cells implies that it may have the capacity to effectively treat chloasma and promote wound healing. To assess the efficacy of vitamin D in chloasma treatment and its impact on the function of skin barrier during the process of wound healing. The research spanned from April 2022 to September 2023, in Shanghai, China, examined 480 individuals who had been diagnosed with chloasma. A double-blind, placebocontrolled clinical trial was utilized to evaluate effectiveness of topical vitamin D3 in treatment of chloasma. Concurrently, randomized control trial investigated the effects of ingested vitamin D3 supplements on the process of wound healing. Transepidermal water loss (TEWL), chloasma severity score changes, wound size reduction and skin hydration levels were critical performance indiators. Statistically, the severity scores of chloasma decreased significantly in the vitamin D treatment group at 3 and 6 months compared with the placebo (p < 0.05). The Vitamin D group exhibited superior wound healing outcomes, including more substantial reduction in lesion size and enhanced skin barrier function, as evidenced by increased skin hydration and decreased TEWL (p < 0.05). Vitamin D substantially mitigated the severity of chloasma and has beneficial effect on wound healing and integrity of the skin barrier. Based on the results obtained, vitamin D exhibited promise as a therapeutic intervention in the field of dermatology, specifically in treatment of chloasma and promotion of wound recovery.
KEYWORDS
chloasma treatment, dermatology, skin barrier function, vitamin D, wound healing
Key Messages The study aimed to evaluate the effectiveness of vitamin D in treating chloasma and enhancing wound healing.
Findings revealed that vitamin D significantly reduced chloasma severity and improved wound healing, as indicated by increased skin hydration and decreased transepidermal water loss.
Song Hee Kim1 Jeonghoon Yun1,2 Woncheol Kim1 Eunsu Seon1 Chanhwi Lee1 Jaejoon Jeon1 Mid Eum Yun3 Keun Hyung Park1,3
1 Sunjin Clinical Research Center, Sunjin Beauty Science Co., Ltd., Seoul, South Korea
2 Faculty of Life Sciences, University of Toronto, Toronto, Ontario, Canada
3 R&D Center, Sunjin Beauty Science Co., Ltd., Seoul, South Korea
Keun Hyung Park (Director, Ph.D), Sunjin Clinical Research Center, Sunjin Beauty Science Co., Ltd., 8F, Gasan Hanwha Bizmetro, 43-14, Gasandigital 2-ro, Geumcheon-gu, Seoul, South Korea.
© 2024 The Author(s). Skin Research and Technology published by John Wiley & Sons Ltd.
Introduction: Ceramides are essential epidermal constituents that play a critical role in skin moisturization treatment as a raw material in cosmetics formulation. Recently, ceramides have been known to be frequently applied in various cosmetic formulations. Despite ceramide’s beneficial characteristics, academic research regarding ceramides and their skin absorption remains insufficient. Therefore, our study conducted clinical research employing Raman spectroscopy to investigate the effects of ceramides on skin absorption to enhance the understanding of ceramides’ dermatological functionality and their topical application in cosmetics science.
Materials and Methods: Twenty healthy individuals with dry skin have participated in this clinical trial. In this double-arm designed trial, the test group received an investigational product with ceramides (5000 ppm) and a control group received an investigational product without the ceramides while all other components remained identical. The subjects visited the clinical research center and acclimatized for 30 min in constant humidity and temperature for equilibrium, subsequently conducting a measurement. Before the trial, the research subject’s target site (lower arm area) was kept clean, devoid of any cosmetic administering 24 h before the trial when investigational product was topically applied.
Results: Our findings with Raman spectroscopy statistically demonstrate that skin absorption amount, speed and depth for both groups improved overall (p < 0.05) after administration of the investigational product. Notably, the test group received an investigational product with ceramides (5000 ppm) indicating superior effectiveness across all parameters compared to a control group from comparison analysis of each parameter (p < 0.05).
Conclusion: This study concludes that ceramide-containing cosmetics provide a beneficial effect on skin absorption via visual and statistical results of Raman spectroscopy
ceramides, cosmetic, Raman spectroscopy, skin absorption, skin clinical research
Ikhwan Kim1,2 , Dong-Min Lee1,2 , Jae-Woo Shin1,3 ,Gyoun-Jung Lee1,3 , Eun-Seong Kim1,3 * and Nam-Young Kim1,2,3 *
1 RFIC Bio Center, Kwangwoon University, Seoul, Republic of Korea, 2 Department Electronic Engineering, Kwangwoon University, Seoul, Republic of Korea, 3 APR Device Center, Seoul, Republic of Korea
OPEN ACCESS
EDITED BY Daniele Tosi, Nazarbayev University, Kazakhstan
REVIEWED BY
Lorenzo Crocco, National Research Council (CNR), Italy Changyul Cheon,
University of Seoul, Republic of Korea
*CORRESPONDENCE Eun-Seong Kim, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 Nam-Young Kim, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
RECEIVED 29 January 2024
ACCEPTED 08 March 2024
PUBLISHED 28 March 2024
CITATION
Kim I, Lee D-M, Shin J-W, Lee G-J, Kim E-S and Kim N-Y (2024), Radio frequency hyperthermia system for skin tightening effect by filled waveguide aperture antenna with compact metamaterials. Front. Bioeng. Biotechnol. 12:1378084.
doi: 10.3389/fbioe.2024.1378084
COPYRIGHT
© 2024 Kim, Lee, Shin, Lee, Kim and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Radio frequency (RF) hyperthermia focuses on raising the target area temperature to a value exceeding 45°C. Collagen is stimulated when the temperature rises to 45°C at the dermal layer, resulting in skin tightening. However, most studies on RF hyperthermia have focused on tumor ablation or using electrodes to radiate an electromagnetic field, which is highly inefficient. This study proposed a noninvasive RF hyperthermia skin-tightening system with a compact metamaterial- filled waveguide aperture antenna. The proposed RF system increased the temperature by 11.6°C and 35.3°C with 20 and 80 W of 2.45 GHz RF power, respectively, within 60 s and exhibited a very focused effective area. Furthermore, a metamaterial was proposed to reduce the size of the waveguide aperture antenna and focus the electromagnetic field in the near-field region. The proposed metamaterial-filled waveguide aperture antenna was compact, measuring 10 mm × 17.4 mm, with a peak gain of 2.2 dB at 2.45 GHz. The measured hyperthermia performance indicated that the proposed RF system exhibited better power- and time-efficient hyperthermia performance than other RF hyperthermia systems in the cosmetic skin lifting commercial market. The proposed RF hyperthermia systems will be applied into a new generation of beauty cosmetic devices.
KEYWORDS RF hyperthermia, metamaterial, skin tightening, beauty device, waveguide aperture antenna
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。